Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
HanAll Biopharma Reports Full-Year 2022 Results and Provides Business Update 2023-02-01 20:00
HanAll Biopharma Reports Third Quarter 2022 Results and Provides Business Update 2022-11-15 20:00
HanAll's Licensed Partner in China Enters Sublicense Agreement with CSPC to Further Accelerate Development of Batoclimab 2022-10-11 19:00
HanAll's Second FcRn Inhibitor HL161ANS to be Added to the Development Program of its Licensed Partner 2022-10-04 19:00
HanAll Biopharma Reports Second Quarter 2022 Results and Provides Business Update 2022-07-29 20:00
HanAll Biopharma Reports First Quarter 2022 Results and Provides Business Update 2022-04-28 19:00
HanAll Biopharma and Daewoong Pharmaceutical Invest in Turn Biotechnologies to Expand Growth Initiative 2022-04-13 08:00
HanAll Biopharma Appoints Almira Chabi as Chief Medical Officer and Chief Development Officer 2022-02-21 22:00
HanAll Biopharma Reports Full-Year 2021 Results and Provides Business Update 2022-01-20 22:00
HanAll Biopharma Reports Third Quarter 2021 Results 2021-10-28 21:00
Daewoong Pharmaceutical and Hanall Biopharma Invest $1M USD in Alloplex Biotherapeutics 2021-08-19 21:00
HanAll Biopharma Reports Second Quarter 2021 Results 2021-07-29 18:44
HanAll Biopharma Reports First Quarter 2021 Financial Results 2021-05-06 21:00
HanAll Biopharma and Harbour BioMed Sign Collaboration and License Agreement to Develop Two Novel Biologic Therapies in Greater China 2017-09-12 13:35
1 2